CORE ONE LABS INC - CLABF STOCK NEWS

Core One Labs Inc. (CSE:COOL, OTC PINK:CLABF) issued a news release on May 4, 2021, addressing potentially manipulative trading activity impacting its stock. IIROC and CSE requested this clarification. The Company analyzed trading patterns but found no conclusive evidence of manipulation causing share price depreciation. Factors other than manipulative trading may have contributed to this decline. The Company is focused on developing psychedelic medicines, notably using its patent-pending thin film oral strip technology, aiming for regulatory approval for treatment of mental health disorders.

Core One Labs Inc. (OTC: CLABF) announced that its subsidiary, Akome Biotech Ltd., has initiated the development of a new psychedelic drug formulation, AKO002, aimed at treating Alzheimer’s Disease. This formulation combines psilocybin with a plant bioactive, believed to have complementary effects. A provisional patent for AKO002 has been filed in the U.S. Alzheimer's is a progressive disorder with no current disease-modifying treatments. Akome's research suggests psychedelics may enhance neuroplasticity and reduce inflammation, offering potential new avenues for treatment.

Core One Labs Inc. (OTC: CLABF) announced its subsidiary, Akome Biotech Ltd., has initiated the development of a next-generation psychedelic drug formulation, AKO002, aimed at treating Alzheimer’s Disease. This formulation combines psilocybin with a plant bioactive, believed to be synergistic in combating Alzheimer’s. A patent application for AKO002 has been filed with the USPTO. Current Alzheimer’s treatments do not alter the disease process, highlighting the potential significance of Akome’s research. CEO Joel Shacker emphasized the revolutionary potential of this formulation for millions affected by the disease.

Core One Labs Inc. (OTC: CLABF) has appointed Dr. Santiago Ferro as the new Chief Medical Officer. Dr. Ferro, with over 20 years of experience in the pharmaceutical and biotech industries, will oversee the company's clinical trials and the commercialization of its psychedelic products. He has a significant background in internal medicine and infectious diseases, previously holding key positions in renowned organizations, including Sanofi Pasteur and Novartis. Core One is focused on developing and marketing psychedelic medicines through innovative delivery systems and psychotherapy integration.

Core One Labs Inc. (OTC: CLABF) has appointed Dr. Santiago Ferro as Chief Medical Officer to lead clinical trials and commercialization of its psychedelic products. Dr. Ferro, with over 20 years in the biotech sector, has significant experience in clinical development and regulatory environments. Core One is focused on bringing psychedelic medicines to market using novel delivery systems, including a patent-pending thin film oral strip for optimal bioavailability. The company aims to advance psychedelic treatments for mental health disorders.

Core One Labs Inc. (OTC PINK:CLABF) has announced that it is unaware of any material changes that could explain its recent share price decline. The company cited potential manipulation techniques including spoofing and wash trading affecting its stock. Core One also highlighted the issue of predatory short selling prevalent among smaller market cap companies and called for regulatory reforms to combat these practices. The company is focusing on developing psychedelic therapies and holds an interest in medical clinics with a substantial patient database.

Core One Labs Inc. (OTC: CLABF) announced the successful acquisition of Akome Biotech Ltd., enhancing its psychedelics research and development division. This acquisition allows Core One to broaden its focus on drug formulations targeting neurological disorders, utilizing Akome’s proprietary cGMP formulations that blend psychedelic compounds with plant bioactives. Akome holds four provisional patents for formulations aimed at treating conditions such as Parkinson’s, Alzheimer's, and depression. This strategic move is expected to meet the needs of millions globally.

Core One Labs has successfully acquired Akome Biotech Ltd., enhancing its psychedelics research capabilities targeting neurological disorders. This acquisition broadens the scope of Core One's drug development efforts, focusing on proprietary formulations that combine psychedelics with plant bioactives. Akome holds four provisional patents for drug formulations addressing Parkinson's Disease, Ischemic Stroke, Alzheimer’s Disease, and depression. The deal involves issuing 3.5 million shares to Akome shareholders, along with additional shares in connection with the transaction.

Core One Labs Inc. has appointed Dr. Dan Polonenko to its Advisory Board to enhance its IP strategy, particularly in biotechnology patents like psilocybin. Dr. Polonenko brings over 20 years of experience in the biotech sector and will assist with patent filings. Additionally, the company reported that its affiliate, Shahcor Health Services, has achieved targets enabling a $1 million bonus, which will be paid via shares. The company is also settling outstanding payables through share issuances, totaling $196,000 in common shares.